Current developments in gastric cancer: from molecular profiling to treatment strategy

Alsina, Maria; Arrazubi, Virginia; Diez, Marc; Tabernero, Josep

Home
→
Recerca
→
Articles, congressos, llibres
→
Articles
→
View Item

dc.contributor	Vall d'Hebron Institut d'Oncologia
dc.contributor	Hospital Universitario de Navarra
dc.contributor	Instituto de Investigación Sanitaria de Navarra (IdiSNA)
dc.contributor	Hospital Universitari Vall d’Hebron (HUVH)
dc.contributor.author	Alsina, Maria
dc.contributor.author	Arrazubi, Virginia
dc.contributor.author	Diez, Marc
dc.contributor.author	Tabernero, Josep
dc.date.accessioned	2024-03-06T09:59:24Z
dc.date.available	2024-03-06T09:59:24Z
dc.date.created	2023
dc.date.issued	2023
dc.identifier.citation	Alsina, M., Arrazubi, V., Diez, M. et al. Current developments in gastric cancer: from molecular profiling to treatment strategy. Nat Rev Gastroenterol Hepatol 20, 155–170 (2023). https://doi.org/10.1038/s41575-022-00703-w	es
dc.identifier.issn	1759-5053
dc.identifier.issn	1759-5045
dc.identifier.uri	http://hdl.handle.net/10854/7829
dc.description	Review
dc.description.abstract	Gastric cancer and gastro-oesophageal junction cancer represent a global health-care challenge. Despite the efficacy of improved chemotherapy and surgical options, these patients still have a poor prognosis. In advanced disease, only trastuzumab and some immune checkpoint inhibitors, such as nivolumab and pembrolizumab in addition to chemotherapy, have demonstrated consistent and reliable efficacy in patients with HER2-positive and PDL1-positive tumours, respectively. In this Review, we discuss the intrinsic characteristics of gastric and gastro-oesophageal cancer from the molecular and clinical perspectives and provide a comprehensive review of previously reported and ongoing phase II and III clinical trials with targeted agents and immunotherapy in advanced and localized settings. Finally, we suggest alternative strategies to help overcome current challenges in precision medicine and to improve outcomes for these patients.	es
dc.format	application/pdf	es
dc.format.extent	16 p.	es
dc.language.iso	eng	es
dc.publisher	SpringerNature	es
dc.rights	Tots els drets reservats	es
dc.subject.other	Càncer	es
dc.subject.other	Immunoteràpia	es
dc.subject.other	Assaigs clínics	es
dc.title	Current developments in gastric cancer: from molecular profiling to treatment strategy	es
dc.type	info:eu-repo/semantics/article	es
dc.identifier.doi	https://doi.org/10.1038/s41575-022-00703-w
dc.rights.accessRights	info:eu-repo/semantics/closedAccess	es
dc.type.version	info:eu-repo/publishedVersion	es
dc.indexacio	Indexat a WOS/JCR	es
dc.indexacio	Indexat a SCOPUS	es